Kinome-wide activity classification of small molecules by deep learning
暂无分享,去创建一个
[1] Martin Romacker,et al. Evolving BioAssay Ontology (BAO): modularization, integration and applications , 2014, Journal of Biomedical Semantics.
[2] L. Urban,et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. , 2014, Lung cancer.
[3] A. Chella,et al. Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report , 2015, Oncology letters.
[4] George Papadatos,et al. Evaluation of machine-learning methods for ligand-based virtual screening , 2007, J. Comput. Aided Mol. Des..
[5] Nagi Ayad,et al. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4 , 2015, Scientific Reports.
[6] John P. Overington,et al. The ChEMBL database: a taster for medicinal chemists. , 2014, Future medicinal chemistry.
[7] Andreas Mayr,et al. Deep Learning as an Opportunity in Virtual Screening , 2015 .
[8] Ravi Iyengar,et al. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. , 2017, Cell systems.
[9] Vasileios Stathias,et al. Sustainable data and metadata management at the BD2K-LINCS Data Coordination and Integration Center , 2018, Scientific Data.
[10] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[11] C. Ruan,et al. Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia. , 2016, Pharmacogenomics.
[12] K. Sauer,et al. Mechanisms of drug resistance in kinases , 2011, Expert opinion on investigational drugs.
[13] Jia Jia,et al. Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. , 2009, Combinatorial chemistry & high throughput screening.
[14] V. Canzonieri,et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy , 2011, The Pharmacogenomics Journal.
[15] Stephan C. Schürer,et al. Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets , 2013, J. Chem. Inf. Model..
[16] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[17] David Wu,et al. Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] Vasileios Stathias,et al. Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data , 2017, Nucleic Acids Res..
[19] Anthony E Klon. Bayesian modeling in virtual high throughput screening. , 2009, Combinatorial chemistry & high throughput screening.
[20] Vijay S. Pande,et al. Massively Multitask Networks for Drug Discovery , 2015, ArXiv.
[21] S. Muskal,et al. High quality, small molecule-activity datasets for kinase research , 2016, F1000Research.
[22] James S. Duncan,et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.
[23] N. James,et al. Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney , 2009, Oncology Research and Treatment.
[24] Rajarshi Guha,et al. Drug target ontology to classify and integrate drug discovery data , 2017, J. Biomed. Semant..
[25] M. Clausen,et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.
[26] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.